Tacrolimus Market Share, Size, Trends, Industry Analysis Report, By Product Type (Injections, Tablets and Capsules, Others); By Application; By End-Use; By Region; Segment Forecast, 2024 - 203
The tacrolimus market size is expected to reach USD 9,683.26 million by 2032, according to a new study by Polaris Market Research. The report “Tacrolimus Market Share, Size, Trends, Industry Analysis Report, By Product Type (Injections, Tablets and Capsules, Others); By Application; By End-Use; By Region; Segment Forecast, 2024 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.
The increasing organ transplantation rates drive the tacrolimus market growth. Tacrolimus is a potent immunosuppressive drug extensively used in transplant patients to prevent the rejection of newly transplanted organs. The continuous advancements in medical research and pharmaceuticals within the tacrolimus market have significantly contributed to improving patient outcomes post-transplantation. These developments have not only enhanced the efficacy of tacrolimus but have also led to the development of more targeted and personalized approaches to immunosuppression. The increasing availability and accessibility of tacrolimus, a medication used to prevent organ rejection after transplantation, has led to a favorable increase in organ transplantation rates. Efforts to simplify transplantation procedures and educate the public on organ donation have also contributed to the tacrolimus market growth.
The advancements in organ transplantation procedures foster the tacrolimus market growth. The need for immunosuppressants has been on the rise due to advancements in minimally invasive transplant procedures, improved organ preservation methods, and higher success rates of transplants. Tacrolimus has emerged as a crucial medication in transplantation medicine because of its effectiveness and fewer side effects in comparison to traditional drugs. With advancements in surgical techniques and post-transplant care, the use of immunosuppressive drugs such as tacrolimus has increased. The demand for tacrolimus has increased due to the growing number of transplant surgeries and the wider acceptance of transplantation as an effective treatment for various medical conditions.
As the geriatric population grows, the demand for medications like tacrolimus is expected to increase. This is because older adults often require organ transplants or face immune-related disorders. Healthcare systems are adapting to meet the evolving healthcare needs of this aging demographic, creating a significant market opportunity for tacrolimus manufacturers and suppliers.
Tacrolimus Market Report Highlights
The tablets and capsules segment held the largest market share in 2023 due to tacrolimus being favorable and easy for patients to consume, ensuring better compliance with medication regimens.
The immunosuppression segment dominated the market in 2023 due to the rising number of organ transplant surgeries.
North America dominated the tacrolimus market, owing to the surge in organ transplants and the presence of the key players in the region.
The key market players include Astellas Pharma Inc., Biocon Ltd., Dr. Reddy's Laboratories Ltd., Glenmark Pharmaceuticals Inc., GlaxoSmithKline plc, LEO Pharma A/S, Novartis AG, Lupin Pharmaceuticals Inc., Panacea Biotec, and Pfizer Inc.
Polaris Market Research has segmented the tacrolimus market report based on product, application, end-use, and region:
Polypropylene Nonwoven Fabrics, Product Type Outlook (Revenue - USD Million, 2019 - 2032)
Injections
Tablets and Capsules
Others
Polypropylene Nonwoven Fabrics, Application Outlook (Revenue - USD Million, 2019 - 2032)
Dermatitis
Immunosuppression
Others
Polypropylene Nonwoven Fabrics, End-Use Outlook (Revenue - USD Million, 2019 - 2032)
Clinics
Hospitals
Others
Polypropylene Nonwoven Fabrics, Regional Outlook (Revenue - USD Million, 2019 - 2032)
North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Indonesia
Australia
Malaysia
Rest of Asia Pacific
Latin America
Argentina
Brazil
Mexico
Rest of Latin America
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa
Rest of Middle East & Africa